Caribou Biosciences (CRBU) Stock
Clinical stage biotech developing gene editing therapies. Here's the price, business snapshot, and what's worth knowing about Caribou Biosciences in August 2026.
Caribou Biosciences (CRBU) is a clinical-stage biotechnology company developing CRISPR-based gene-editing platforms and therapeutic candidates. The business focuses on creating engineered cell therapies and in vivo programmes that aim to correct or modify genes to treat disease. With a market capitalisation of roughly $264.5 million, Caribou sits in the small-cap, high-volatility segment of the biotech market: scientific milestones, trial results and partner deals can move the shares sharply. Key considerations for investors include clinical and regulatory risk, the long timelines typical of drug development, capital requirements, and the importance of collaborations or licences to scale commercialisation. Intellectual property and the company’s technical platform are central value drivers, but outcomes are binary and uncertain. This summary is for educational purposes only and not personalised financial advice; investors should assess suitability, diversification and time horizon and consult a qualified adviser before acting.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Caribou Biosciences' stock, indicating strong potential for price increase.
Financial Health
Caribou Biosciences has modest revenue and cash flow, indicating steady but unspectacular financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Matter
Progress in trials can re-rate the stock quickly, though trial outcomes are uncertain and may not lead to approval.
Platform Potential
Caribou’s CRISPR platform is a core value driver; strong IP and partnerships can accelerate development but do not remove scientific risk.
Partnerships & Scale
Collaborations with larger pharmas can provide validation and funding, yet commercialisation remains long-term and capital-intensive.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
